Sven Inerot

1.0k total citations
21 papers, 888 citations indexed

About

Sven Inerot is a scholar working on Rheumatology, Cell Biology and Molecular Biology. According to data from OpenAlex, Sven Inerot has authored 21 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 12 papers in Cell Biology and 8 papers in Molecular Biology. Recurrent topics in Sven Inerot's work include Proteoglycans and glycosaminoglycans research (12 papers), Osteoarthritis Treatment and Mechanisms (11 papers) and Glycosylation and Glycoproteins Research (5 papers). Sven Inerot is often cited by papers focused on Proteoglycans and glycosaminoglycans research (12 papers), Osteoarthritis Treatment and Mechanisms (11 papers) and Glycosylation and Glycoproteins Research (5 papers). Sven Inerot collaborates with scholars based in Sweden, United States and Italy. Sven Inerot's co-authors include Dick Heinegård, S E Olsson, Mats Paulsson, Joel A. Block, Julia Asp, Anders Lindahl, James H. Kimura, A Franzén, Steven Gitelis and Gert Lindblad and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Bone and Joint Surgery and Biochemical Journal.

In The Last Decade

Sven Inerot

21 papers receiving 825 citations

Peers

Sven Inerot
Ole W. Wiebkin Australia
Y Yutani Japan
Anthony M. DeLise United States
K. Király Finland
Peter McCroskery United States
Ole W. Wiebkin Australia
Sven Inerot
Citations per year, relative to Sven Inerot Sven Inerot (= 1×) peers Ole W. Wiebkin

Countries citing papers authored by Sven Inerot

Since Specialization
Citations

This map shows the geographic impact of Sven Inerot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Inerot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Inerot more than expected).

Fields of papers citing papers by Sven Inerot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Inerot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Inerot. The network helps show where Sven Inerot may publish in the future.

Co-authorship network of co-authors of Sven Inerot

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Inerot. A scholar is included among the top collaborators of Sven Inerot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Inerot. Sven Inerot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asp, Julia, Camilla Brantsing, Maria Serena Benassi, et al.. (2005). Evaluation of p16 and Id1 status and endogenous reference genes in human chondrosarcoma by real-time PCR.. PubMed. 27(6). 1577–82. 12 indexed citations
2.
Asp, Julia, Camilla Brantsing, Maria Serena Benassi, et al.. (2001). Changes inp14ARF do not play a primary role in human chondrosarcoma tissues. International Journal of Cancer. 93(5). 703–705. 8 indexed citations
3.
Asp, Julia, Sven Inerot, Joel A. Block, & Anders Lindahl. (2001). Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma. Journal of Orthopaedic Research®. 19(1). 149–154. 27 indexed citations
4.
Asp, Julia, Luca Sangiorgi, Sven Inerot, et al.. (2000). Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. International Journal of Cancer. 85(6). 782–786. 60 indexed citations
5.
Asp, Julia, Maria Thornemo, Sven Inerot, & Anders Lindahl. (1998). The helix‐loop‐helix transcription factors Id1 and Id3 have a functional role in control of cell division in human normal and neoplastic chondrocytes. FEBS Letters. 438(1-2). 85–90. 30 indexed citations
6.
Block, Joel A., et al.. (1996). Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. Cancer Letters. 105(1). 77–90. 24 indexed citations
7.
Block, Joel A., Sven Inerot, & James H. Kimura. (1992). Heterogeneity of keratan sulfate substituted on human chondrocytic large proteoglycans.. Journal of Biological Chemistry. 267(11). 7245–7252. 9 indexed citations
8.
Inerot, Sven, et al.. (1991). Proteoglycan alterations during developing experimental osteoarthritis in a novel hip joint model. Journal of Orthopaedic Research®. 9(5). 658–673. 26 indexed citations
9.
Block, Joel A., Sven Inerot, Steven Gitelis, & James H. Kimura. (1991). The Effects of Long Term Monolayer Culture on the Proteoglycan Phenotype of a Clonal Population of Mature Human Malignant Chondrocytes. Connective Tissue Research. 26(4). 295–313. 8 indexed citations
10.
Inerot, Sven & Inge Axelsson. (1991). Structure and Composition of Proteoglycans From Human Annulus Fibrosus. Connective Tissue Research. 26(1-2). 47–63. 12 indexed citations
11.
Block, Joel A., Sven Inerot, Steven Gitelis, & James H. Kimura. (1991). Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture.. Journal of Bone and Joint Surgery. 73(5). 647–658. 61 indexed citations
12.
Saito, Seiji, et al.. (1988). A long term culture of cells from Swarm rat chondrosarcoma in suspension after alginate preculture.. The Keio Journal of Medicine. 37(3). 282–298. 6 indexed citations
13.
Inerot, Sven & Dick Heinegård. (1987). The Normal Variation in Structure and Composition of Canine Hip Articular Cartilage Proteoglycans. Collagen and Related Research. 7(6). 423–433. 4 indexed citations
14.
Heinegård, Dick, Sven Inerot, Jörgen Wieslander, & Gert Lindblad. (1985). A method for the quantification of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease. Scandinavian Journal of Clinical and Laboratory Investigation. 45(5). 421–427. 58 indexed citations
15.
Paulsson, Mats, Sven Inerot, & Dick Heinegård. (1984). Variation in quantity and extractability of the 148-kilodalton cartilage protein with age. Biochemical Journal. 221(3). 623–630. 28 indexed citations
16.
Inerot, Sven & Dick Heinegård. (1983). Bovine Tracheal Cartilage Proteoglycans. Variations in Structure and Composition with Age. Collagen and Related Research. 3(3). 245–262. 58 indexed citations
17.
Franzén, A, et al.. (1981). Variations in the composition of bovine hip articular cartilage with distance from the articular surface. Biochemical Journal. 195(3). 535–543. 84 indexed citations
18.
Heinegård, Dick, et al.. (1981). A novel low-molecular weight chondroitin sulphate proteoglycan isolated from cartilage. Biochemical Journal. 197(2). 355–366. 122 indexed citations
19.
Heinegård, Dick, Inge Axelsson, & Sven Inerot. (1979). Skeletal keratan sulfate peptides from different tissues Characterization and alkaline degradation. Biochimica et Biophysica Acta (BBA) - Protein Structure. 581(1). 122–127. 5 indexed citations
20.
Inerot, Sven, et al.. (1978). Articular-cartilage proteoglycans in aging and osteoarthritis. Biochemical Journal. 169(1). 143–156. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026